Non–Small Cell Lung Cancer Coverage from Every Angle

Martin Reck, MD, PhD, on NSCLC: Results From Three Key Trials

Posted: Wednesday, October 4, 2017

Martin Reck, MD, PhD, of the LungenClinic, discusses study finding on fixed-duration vs continuous nivolumab in patients with advanced non-small cell lung cancer; nab-paclitaxel with or without CC-486 or durvalumab in previously treated patients with advanced NSCLC; and updated results from KEYNOTE-021 on pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous NSCLC.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.